

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 44D0673604	(X3) Date Survey Completed 05/10/2019
Name of Provider or Supplier Janice S Algea, Md	Street Address, City, State 8222 Us Hwy 51 North, Millington, TN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory participation for two consecutive events for the white blood cell (WBC) analyte, resulting in the first unsuccessful proficiency testing (PT) occurrence for the WBC analyte. (Refer to D2130)</p>
D2130	<p>HEMATOLOGY CFR(s): 493.851(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.</p>

This STANDARD is not met as evidenced by:

Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and the laboratory's 2018 and 2019 proficiency testing (PT) records the laboratory failed to maintain satisfactory performance for the white blood cell (WBC) analyte for 2018 event three and 2019 event one, resulting in the first unsuccessful occurrence. The findings include: 1) Review of the CMS155 report revealed failing scores for the WBC analyte as follows: 2018 event three=60%, 2019 event one=60%. 2) Review of the 2018 event three PT evaluation report revealed sample numbers QBC-11 and QBC-12 scored as unacceptable, resulting in an overall score of 60%. 3) Review of the 2019 event one PT evaluation report revealed sample numbers QBC-04 and QBC-05 scored as unacceptable, resulting in an overall score of 60%.